{
    "id": 26879,
    "fullName": "ENG positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ENG positive indicates the presence of the ENG gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2022,
        "geneSymbol": "ENG",
        "terms": [
            "ENG",
            "END",
            "HHT1",
            "ORW1"
        ]
    },
    "variant": "positive",
    "createDate": "08/17/2017",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11738,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TRC 105 and Nexavar (sorafenib) combination treatment resulted in an overall response rate of 21% (5/24), median progression-free survival of 3.8 months, and median overall survival of 15.5 months in patients with hepatocellular carcinoma (PMID: 28465443).",
            "molecularProfile": {
                "id": 28203,
                "profileName": "ENG positive"
            },
            "therapy": {
                "id": 2389,
                "therapyName": "Carotuximab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9755,
                    "pubMedId": 28465443,
                    "title": "Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28465443"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28203,
            "profileName": "ENG positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}